Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
7.84
0.00 (0.00%)
At close: Feb 11, 2026, 4:00 PM EST
7.89
+0.05 (0.64%)
After-hours: Feb 11, 2026, 5:16 PM EST
Kura Oncology Revenue
Kura Oncology had revenue of $20.75M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $104.03M. In the year 2024, Kura Oncology had annual revenue of $53.88M.
Revenue (ttm)
$104.03M
Revenue Growth
n/a
P/S Ratio
6.59
Revenue / Employee
$541,818
Employees
192
Market Cap
682.22M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 53.88M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionKURA News
- 5 days ago - Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 20 days ago - Kura Oncology: Safety Profile Of Komzifti Supports My Upgrade To Strong Buy - Seeking Alpha
- 4 weeks ago - Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones - GlobeNewsWire
- 2 months ago - Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript - Seeking Alpha
- 2 months ago - Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML - GlobeNewsWire
- 2 months ago - Kura Oncology: A Cautious Buy - Seeking Alpha
- 2 months ago - Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia - GlobeNewsWire
- 2 months ago - Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data - Seeking Alpha